Swiss President ready to negotiate with Trump at WEF

Swiss President Guy Parmelin said he is prepared to negotiate with U.S. President Donald Trump on the sidelines of the WEF in Davos after the Federal Council approved a definitive negotiating mandate on tariffs. Bern and Washington agreed in November to cut U.S. taxes on Swiss products from 39% to 15%, but a formal agreement must be concluded by March 31 to lock in the reduction; discussions could proceed quickly if U.S. representatives are willing. The WEF runs Jan. 19–23, where Trump will lead a large delegation and Swiss ministers will attend.

Analysis

Market structure: A confirmed cut of US tariffs on Swiss goods from 39% to 15% is a clear win for Swiss exporters with large US revenue exposure — think Roche (ROG / RHHBY), Novartis (NOVN / NVS), Richemont (CFR.SW) and Swatch (UHR.SW) — improving price competitiveness and margin realizations in the US by an estimated 2–6% EPS benefit over 12 months for pharma/medtech and a potential 10–20% volume uplift for luxury watches over 12–18 months. US domestic producers in affected categories (high-end watches, precision instruments) could lose share, pressuring margins. Credit spreads on Swiss corporate debt should tighten modestly (10–30bps) if deal certainty rises.

Risk assessment: Immediate risk is political (deal collapses pre–Mar 31) and reputational (Trump rhetoric at WEF) — low-probability but high-impact downside that could remove anticipated upside; monitor formal sign-off by Mar 31. Time horizons: knee-jerk around WEF (Jan 19–23); resolution window to Mar 31 (decision point); structural effects accrue over Q2–Q4 2026. Hidden dependencies: USD/CHF moves (a CHF appreciation >2% could wipe out export margin gains), US customs implementation lag, and possible state-level or sector carve-outs.

Trade implications: Tactical: establish 2–3% long positions in NVS (NYSE) and ROG (SIX/RHHBY OTC) ahead of the March 31 deadline, targeting 5–12% upside if confirmed; set hard stop-loss at -8% and trim if CHF strengthens >2% vs USD. Pair trade: long CFR.SW (luxury watches) vs short LVMH (MC.PA) 1:1 to play tariff-driven share shift; use June 2026 call spreads (5–10% OTM) on NVS/ROG to capture upside with defined risk. Size exposure so total Swiss-export sensitive eq. <=5% of portfolio.

Contrarian angles: Consensus may underprice implementation friction and FX offset — markets often rally on headline deals then reverse on currency moves; expect overstated immediate equity gains if CHF firming occurs. Historical parallel: 2018 US-EU tariff threats produced quick share rotation but modest long-term structural change; therefore prefer option-defined bullish positions (call spreads) over naked longs. Unintended consequence: stronger CHF or US importers shifting to local sourcing could mute gains; reduce positions if CHF >1.02 USD/CHF (≈2% move) or if no formal text filed by Mar 31.

Key Decisions for Investors

• Establish a 2–3% long position in Novartis (NVS) and a 2% long in Roche (ROG / RHHBY OTC) split proportionally (total Swiss pharma exposure 4–5% of portfolio) before March 31, 2026; target 5–12% upside on confirmation, implement 8% stop-loss and trim half at +8%.
• Initiate a relative value pair: long Richemont (CFR.SW) 1% vs short LVMH (MC.PA) 1% to exploit tariff-driven share gains in US luxury; re-evaluate after March 31 or if CHF strengthens >2% vs USD.
• Buy June 2026 5–10% OTM call spreads on NVS and ROG (size = 0.5–1% notional each) to capture upside with capped downside; alternatively use a risk-reversal (sell 5% OTM put / buy 5% OTM call) if implied volatility rises >20% from current levels.
• Reduce/hedge Swiss-export sensitive exposure if either (a) no formal agreement text deposited by March 31, 2026, or (b) USD/CHF moves such that CHF appreciates >2% (e.g., USD/CHF < 0.98); implement CHF hedge (sell CHF forwards for 3–6 months) if exposure >3% of portfolio.